Abstract: An inhalation device comprising a housing, a sensor, a microcontroller, and an actuating device controlled by the microcontroller; the housing comprises a mouthpiece having an opening connected to a passage in said housing, wherein the other end of the passage provides an opening for a cartridge; said sensor being in communication with the microprocessor and configured to detect a parameter based on an action to the mouthpiece, and wherein a parameter being reached, the microcontroller engages the actuating device which engages the cartridge to deliver medication through the passage and out of the mouthpiece.

Abstract: Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of nucleic acid programmable DNA binding proteins (napDNAbp), e.g., Cpf1 or variants thereof, and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a napDNAbp (e.g., CasX, CasY, Cpf1, C2c1, C2c2, C2C3, and Argonaute) and nucleic acid editing proteins or domains, are provided.

Abstract: The inefficient delivery of proteins into mammalian cells remains a major barrier to realizing the therapeutic potential of many proteins. Previously, it has been demonstrated that superpositively charged proteins are efficiently endocytosed and can bring associated proteins and nucleic acids into cells. The vast majority of cargo delivered in this manner, however, remains in endosomes and does not reach the cytosol. The present invention provides endosomal escape peptides that enhance endosomal escape and cytosolic delivery of proteins and other agents of interest. In one aspect, described herein are novel fusion proteins comprising endosomal escape peptides fused to proteins and other agents of interest for delivery to a cell. Also provided herein are methods and compounds useful in preparing the fusion proteins, as well as pharmaceutical compositions and uses of the fusion proteins.

Abstract: The present invention generally relates to a controlled fluidic device to develop spatially complex environments to enhance the rate of evolution in cell populations. The method further provides an enhanced understanding in the emergence, for example, drug resistance during cancer chemotherapy.

Abstract: Catalysts useful in transforming biomass to bio-oil are disclosed, as are methods for making such catalysts, and methods of transforming biomass to bio-oil. The catalysts are especially useful for, but are not limited to, microwave- and induction-heating based pyrolysis of biomass, solid waste, and other carbon containing materials into bio-oil. The catalysts can also be used for upgrading the bio-oil to enhance fuel quality.

Abstract: Provided herein are methods for analysis of target cells on a population or individual basis, including before and after contact with a stimulus in order to determine the effect of such stimulus on the target cells. Also provided are devices for performing such methods. The analysis methods involve identifying and measuring or tracking morphological changes that occur in target cells over a period of time. Tracking is accomplished using imaging systems capable of imaging target cells individually over a period of time either continuously or at discrete intervals of time.

Abstract: The methods and compositions described herein relate to the measurement of factor VIII (fVIII) levels and/or activity.

Abstract: Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.

Abstract: Methods and systems for detecting overstride in runners include measuring, using an inertial measurement unit affixed to a shank of a person, an acceleration and an angle of the shank during a stride, monitoring, using a microprocessor, the shank acceleration measurements to detect an acceleration profile indicative of the corresponding foot making initial contact with the ground during the stride, determining, using the microprocessor, the corresponding shank angle at initial contact from the shank angle measurements, comparing, using the microprocessor, the shank angle at initial contact to a threshold shank angle, and identifying, using the microprocessor, an overstride of the corresponding leg if the shank angle at initial contact exceeds the threshold shank angle.

Abstract: Embodiments of the invention include methods of treating, preventing, and/or reducing the risk of fibrosis in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction of the risk of fibrosis. In at least particular cases, the small molecules are inhibitors of STAT3.

Abstract: The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins further comprise a nuclear localization sequence (NLS), and/or an inhibitor of base repair, such as, a nuclease dead inosine specific nuclease (dISN).

Abstract: A method of preparing a cupric oxide semiconductor. The method includes providing a substrate having a first surface, forming a cuprous oxide layer on the first surface, converting the cuprous oxide layer into a cupric oxide layer via an oxidation reaction, and depositing additional cupric oxide on the cupric oxide layer, which serves as a seed layer, to yield a cupric oxide film, thereby obtaining a cupric oxide semiconductor. Also disclosed are a cupric oxide semiconductor thus prepared and a photovoltaic device including it.

Abstract: A system for dielectric testing of wine in a bottle includes (a) a coaxial probe for interrogating the wine, wherein the coaxial probe has an open end for contacting an exterior surface of the bottle, and (b) a measurement module for determining a dielectric property associated with the wine by generating and measuring radio waves propagating through the coaxial cable. A method for dielectric testing of wine in a bottle includes measuring a radio-wave reflection signal associated with the wine by interrogating the wine, through the bottle, with radio waves, and determining a dielectric property associated with the wine from the radio-wave reflection signal. A probe for radio-wave interrogation of wine in a bottle has an inner conductor, an outer conductor, and an open end with curvature matching the curvature of an exterior surface of the bottle.

Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

Abstract: Embodiments of the present disclosure pertain to conductive textiles that include a textile component with a plurality of fibers; and metal-organic frameworks associated with the fibers of the textile component in the form of a conductive network. Metal-organic frameworks may have a two-dimensional structure and a crystalline form. Metal-organic frameworks may be conformally coated on the fibers of the textile component. Additional embodiments of the present disclosure pertain to methods of sensing an analyte in a sample by exposing the sample to a conductive textile; and detecting the presence or absence of the analyte by detecting a change in a property of the conductive textile, and correlating the change in the property to the presence or absence of the analyte. The analyte in the sample may reversibly associate with the conductive textile. The association may also result in filtration, pre-concentration, and capture of the analyte by the conductive textile.

Abstract: Some embodiments provide an image sensor that includes (i) quanta image sensor having an array of jots and configured for spatial and temporal oversampling, and (ii) a polarization filter array monolithically integrated with the quanta image sensor, so as to provide for a polarization image sensor. The image sensor may also include a color filter array.

Abstract: The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds libraries thereof. The synthesis of these novel stabilized compounds involves (1) synthesizing a peptide from a selected number of natural or non-natural amino acids, wherein said peptide comprises at least two moieties capable of undergoing reaction to promote carbon-carbon bond formation; and (2) contacting said peptide with a reagent to generate at least one crosslinker and to effect stabilization of a secondary structure motif. The present invention, in a preferred embodiment, provides stabilized p53 donor helical peptides. Additionally, the present invention provides methods for disrupting the p53/MDM2 binding interaction comprising (1) providing a crosslinked stabilized ?-helical structure; and (2) contacting said crosslinked stabilized ?-helical structure with MDM2.

Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.

Abstract: Provided herein are 3-phenyl-7-hydroxy-isocoumarin compounds which are MIF inhibitors; compositions comprising said inhibitors and methods for treating or preventing diseases associated with MIF.

Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.